- Home
- FNLC vs FDMT Comparison
FNLC vs FDMT Comparison
Compare FNLC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- FDMT
- Stock Information
- Founded
- FNLC 1864
- FDMT 2013
- Country
- FNLC United States
- FDMT United States
- Employees
- FNLC N/A
- FDMT N/A
- Industry
- FNLC Major Banks
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- FDMT Health Care
- Exchange
- FNLC Nasdaq
- FDMT Nasdaq
- Market Cap
- FNLC 284.0M
- FDMT 192.2M
- IPO Year
- FNLC 1999
- FDMT 2020
- Fundamental
- Price
- FNLC $25.82
- FDMT $4.32
- Analyst Decision
- FNLC
- FDMT Buy
- Analyst Count
- FNLC 0
- FDMT 10
- Target Price
- FNLC N/A
- FDMT $32.33
- AVG Volume (30 Days)
- FNLC 26.6K
- FDMT 418.9K
- Earning Date
- FNLC 07-23-2025
- FDMT 08-07-2025
- Dividend Yield
- FNLC 5.54%
- FDMT N/A
- EPS Growth
- FNLC 1.61
- FDMT N/A
- EPS
- FNLC 2.52
- FDMT N/A
- Revenue
- FNLC $82,116,000.00
- FDMT $23,000.00
- Revenue This Year
- FNLC N/A
- FDMT $13,048.65
- Revenue Next Year
- FNLC N/A
- FDMT N/A
- P/E Ratio
- FNLC $10.25
- FDMT N/A
- Revenue Growth
- FNLC 5.28
- FDMT N/A
- 52 Week Low
- FNLC $22.11
- FDMT $2.24
- 52 Week High
- FNLC $31.05
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- FNLC 57.54
- FDMT 57.43
- Support Level
- FNLC $25.44
- FDMT $3.86
- Resistance Level
- FNLC $27.58
- FDMT $4.48
- Average True Range (ATR)
- FNLC 0.66
- FDMT 0.28
- MACD
- FNLC 0.12
- FDMT 0.01
- Stochastic Oscillator
- FNLC 60.05
- FDMT 89.81
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.